Skip to main content
SpringerLink
Log in

Comparing the Diagnostic Value of the Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in Women with an Adnexal Mass

  • Original Article
  • Published:
Indian Journal of Gynecologic Oncology Aims and scope Submit manuscript

Abstract

Purpose

Ovarian cancer is the fifth leading cause of cancer death among women worldwide. This study aimed to compare the diagnostic value of the risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in women with an adnexal mass.

Methods

This cross-sectional study investigated 245 patients with adnexal mass in Afzalipour Hospital, Kerman, Iran, from 2016 to 2017. Before surgery, 10 cc of blood was taken from each patient. Tumor markers were measured using luminescence immunochemistry with HE4 and CA-125 kits. After surgery, tissue samples were sent to a medical diagnostic laboratory. World Health Organization criteria were applied for pathological classification. Based on CA-125 and HE4 levels and ultrasound findings and menopausal status of patients, ROMA and RMI were used to calculate the malignancy probability in each patient.

Results

The average age of cases was 40.88 ± 14 years. Most tumors were benign (45%). The rate of mass metastasis was 2%. The mean levels of HE4 and CA-125 were 117.52 ± 161.49 and 160.945 ± 302.49, respectively. ROMA was more sensitive than RMI for diagnosis of malignancies, borderline and endometriosis. ROMA was of higher sensitivity and specificity for diagnosis of ovarian cancer in postmenopausal patients. Both ROMA and RMI were of higher sensitivity, specificity, positive and negative predictive values for diagnosis of malignancies.

Conclusion

ROMA is more sensitive than RMI for the diagnosis of ovarian cancer. Accordingly, it can be applied as an appropriate method for diagnosing ovarian cancer as well as for treatment decisions in gynecological surgery wards.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Muinao T, Boruah HPD, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826.

    Article  Google Scholar 

  2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  Google Scholar 

  3. Badgwell D, Bast R. Early detection of ovarian cancer. Dis Markers. 2007;23(5–6):397–410.

    Article  CAS  Google Scholar 

  4. Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. The Lancet. 2014;384(9951):1376–88.

    Article  Google Scholar 

  5. Siegiel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    Article  Google Scholar 

  6. Zhang L, Chen Y, Wang K. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2019;43(2):135–44.

    Article  Google Scholar 

  7. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Can Res. 2003;63(13):3695–700.

    Google Scholar 

  8. Sölétormos G, Duffy MJ, Hassan SOA, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43–51.

    Article  Google Scholar 

  9. Priyanka V, Karthiga S, Sivanesan B, et al. A Comparative Study of RMI and ROMA in women presenting with an adnexal mass. Indian J Gynecol Oncol. 2018;16(1):4.

    Article  Google Scholar 

  10. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–6.

    Article  CAS  Google Scholar 

  11. Dijmărescu AL, Gheorman V, Manolea MM, et al. Serological and immunohistochemical biomarkers for discrimination between benign and malignant ovarian tumors. Rom J Morphol Embryol. 2019;60(4):1163–74.

    PubMed  Google Scholar 

  12. Al-Ogaidi I, Gou H, Aguilar ZP, et al. Detection of the ovarian cancer biomarker CA-125 using chemiluminescence resonance energy transfer to graphene quantum dots. Chem Commun. 2014;50(11):1344–6.

    Article  CAS  Google Scholar 

  13. Perez BH, Gipson IK. Focus on molecules: human mucin MUC16. Exp Eye Res. 2008;87(5):400.

    Article  CAS  Google Scholar 

  14. Ferraro S, Braga F, Lanzoni M, et al. Serum human epididymis protein 4 versus carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66(4):273–81.

    Article  CAS  Google Scholar 

  15. Meray O, Türkçüoğlu I, Meydanlı MM, et al. Risk of malignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor. J Turk German Gynecol Assoc. 2010;11(1):22.

    Google Scholar 

  16. Kotowicz B, Fuksiewicz M, Sobiczewski P, et al. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages. Eur J Obstetr Gynecol Reprod Biol. 2015;194:141–6.

    Article  CAS  Google Scholar 

  17. Gizzo S, Berretta R, Di Gangi S, et al. Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicenter case-control study. Biomed Res Int. 2014;2014:803598.

    PubMed  PubMed Central  Google Scholar 

  18. Nassir M, Darb-Esfahani S, Richter R, et al. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network. Anticancer Res. 2013;33(4):1673–7.

    PubMed  Google Scholar 

  19. Al Musalhi K, Al Kindi M, Al Aisary F, et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Med J. 2016;31(5):336.

    Article  Google Scholar 

  20. Wang J, Gao J, Yao H, et al. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumor Biol. 2014;35(6):38–127.

    Google Scholar 

Download references

Acknowledgements

The authors thank the staff and participants of this study for their important contributions.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

    Zahra Honarvar

  2. Kerman University of Medical Sciences, Kerman, Iran

    Mahdokht Monshi

  3. Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran

    Fatemeh Karami Robati

Authors
  1. Zahra Honarvar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahdokht Monshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatemeh Karami Robati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zahra Honarvar.

Ethics declarations

Conflict of interests

The authors declare that they have no conflict of interests.

Consent to participate

Informed consent was taken from all patients.

Ethics approval

This study was approved by the Ethics Committee of Kerman University of Medical Sciences in Iran (Ethical Code: IR.KMU. AH.REC.1396.1553).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honarvar, Z., Monshi, M. & Karami Robati, F. Comparing the Diagnostic Value of the Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in Women with an Adnexal Mass. Indian J Gynecol Oncolog 19, 56 (2021). https://doi.org/10.1007/s40944-021-00514-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40944-021-00514-y

Keywords

Search

Navigation